Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like
Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...
Fintel on MSN1d
William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation
Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...
BiomX (PHGE) Expected to Announce Earnings on Tuesday
BiomX (NYSEAMERICAN:PHGE – Get Free Report) is anticipated to announce its earnings results before the market opens on ...
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call
Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
Inflammation and Scarring of the Bile Ducts: Causes, Diagnosis, and Treatments
Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...
pharmaphorum2d
FDA clears Ipsen’s primary biliary cholangitis drug
Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).
Medscape2d
Microbiological Analysis of Bile during Cholangiography
The choice of antibiotics used to reduce the risk of cholangitis tends to be empirically ... drainage of the biliary tree remains the primary goal of endoscopic retrograde cholangiopancreatography ...